Marta Cipriani | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
A Flexible Parametric Approach to Synthetic Patients Generation in Clinical Trials		2025
Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients	EJHAEM	2024
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial	LEUKEMIA	2024
Current Knowledge on Breast Implant-Associated Anaplastic Large Cell Lymphoma: Evidence from Italian Ministry of Health Registry Data	AESTHETIC PLASTIC SURGERY	2024
Health-Related Quality of Life and Financial Burden in Ethiopian Patients With Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors: A Cross-Sectional Study	JCO GLOBAL ONCOLOGY	2024
Digital Twins As Control Groups to Accelerate Assessment of Safety and Efficacy of Novel Treatment Strategies in Ph-Negative Acute Lymphoblastic Leukemia	BLOOD	2024
Addition of venetoclax to FLAI induction chemotherapy (VFLAI) improves survival in patients with intermediate and high-risk AML vs FLAI and 3+7: A GIMEMA Italian cooperative analysis	JOURNAL OF CLINICAL ONCOLOGY	2023
Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting	BLOOD ADVANCES	2023
Pseudo-observations in survival analysis	Book of short papers SIS 2023	2023
S159: HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS: RESULTS FROM THE EURO-SKI STUDY	HEMASPHERE	2023
P495: UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE	HEMASPHERE	2023
P523: The comparison of VFLAI, FLAI and 3 + 7 regimens by multilevel propensity score weighting highlights the benefit of the addition of venetoclax in no low risk aml treated in Gimema trials real world	HEMASPHERE	2023
P499: APPLICABILITY OF 2022 CLASSIFICATIONS OF ACUTE MYELOID LEUKEMIA IN THE REAL-WORLD SETTING	HEMASPHERE	2023
The Promotoer, a brain-computer interface-assisted intervention to promote upper limb functional motor recovery after stroke: a statistical analysis plan for a randomized controlled trial	TRIALS	2023
Unraveling the Impact of 2022 Classifications on Secondary Acute Myeloid Leukemia: Assessing the True Qualification Power of Diagnostic Qualifiers	BLOOD	2023
A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial	TRIALS	2023
The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials	BLOOD	2022
Health-Related Quality of Life and Financial Burden of Ethiopian Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors	BLOOD	2022